AR-A014418 inhibits the expression of SOX2 and promotes the sensitivity of chondrosarcoma to cisplatin
LIU Fanrong1, TENG Honglin1, XIAO Jianru1, 2.
1.Department of Spine Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China; 2.Department of Orthopedic Oncology, Shanghai
Changzheng Hospital, Shanghai 200003, China
LIU Fanrong,TENG Honglin,XIAO Jianru. AR-A014418 inhibits the expression of SOX2 and promotes the sensitivity of chondrosarcoma to cisplatin[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2023, 53(4): 291-297,304.
Abstract：Objective: To investigate the effect of GSK3β gene on human chondrosarcoma cell lines HCS 2/8 and SW 1353 by cell experiments. Methods: CCK-8 and colony formation assay were used to detect cell proliferation ability; Transwell assay was used to detect cell invasion ability; wound-healing assay was used to detect cell migration ability; Western blot was used to detect changes of SOX2 in cells; combination experiments were made to verify the effect of AR-A014418 combined with cisplatin. Results: Knockdown of GSK3β significantly inhibited the proliferation and invasion ability of chondrosarcoma (P<0.05). With GSK3β knockdown, the protein expression of SOX2 in cells decreased (P<0.05), and its mRNA level did not change significantly (P>0.05). AR-A014418 could effectively inhibit the expression of SOX2 in CS cells, and the combination of AR and cisplatin produced significant effect. Conclusion: Knockdown of GSK3β can inhibit the protein expression of SOX2 and promote the sensitivity of chondrosarcoma to chemotherapy. As a specific inhibitor of GSK3β, AR-A014418 has the function of killing chondrosarcoma cells, which has good combination effect with cisplatin.
